Kyowa Hakko Kirin Co. | Date: 2015-05-26
The invention provides a method of activating PPAR and a method of treating or preventing a disease associated with PPAR by administering a tricyclic compound having a PPAR agonist activity, which is represented by the formula (I) wherein Z represents a single bond or the like, Y represents a hydrogen atom, lower alkyl optionally having substituent(s) or the like, X represents a hydrogen atom or the like, A represents aryl or the like, B and C are the same or different and each represents an aromatic carbocycle or the like, R
Kyowa Hakko Kirin Co. | Date: 2015-08-19
The present invention relates to an antibody or antibody fragment comprising novel Cys residue, to which a hydrophilic macromolecular group or amphipathic macromolecular group can be bound at a high efficiency. In addition, the present invention relates to a monoclonal antibody modified product or an antibody fragment modified product in which cysteine residue is chemically modified.
Kyowa Hakko Kirin Co. | Date: 2015-11-25
The present invention can provide a monoclonal antibody which comprises a heavy chain constant region which is IgG2 wherein valine at position 234, glutamine at position 237 and proline at position 331 are at least substituted with alanine, alanine and serine, respectively (numbering is based on the EU index of Kabat et al); has an agonist activity; and binds to human CD40.
ArQule and Kyowa Hakko Kirin Co. | Date: 2015-07-24
The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound in combination with a therapeutically effective amount of a second anti-proliferative agent.
Kyowa Hakko Kirin Co. | Date: 2015-08-18
The present invention provides a cationic lipid, which allow nucleic acids to be easily introduced into cells, represented by formula (I)